Let's conquer your financial goals together...faster. In the short term, CRISPR is far ahead of EDITAS in the development of its therapies. (NTLA), and Better Buy: CRISPR Therapeutics vs. Editas Medicine, 2 Game-Changing Biotech Stocks That May Make You Rich. (ticker: CRSP)—co-founded by Charpentier—as well as Caribou Biosciences, Mammoth Biosciences, and Scribe Therapeutics—all co-founded by Doudna. Strategic partnerships are a core component of our strategy to allow us to access capabilities and resources to support our therapeutic programs. Another therapy, EDIT-201, according to Editas, is an healthy-donor NK (natural killer) cell medicine, implanted into patients for the treatment of solid tumors. It has nine product candidates in its development pipeline to treat hemoglobinopathies (blood disorders affecting the hemoglobin), cancers, diabetes, and rare genetic diseases. Just on Tuesday, her privately held Scribe Therapeutics announced a partnership with Description: CTX001 is an autologous CRISPR/Cas9 gene-edited hematopoietic stem cell therapy in development for patients suffering from β-thalassemia and sickle cell disease, Ownership: Co-development and co-commercialization with Vertex, For more information on CTX001 please click here, Description: CTX110 is an allogeneic CRISPR/Cas9 gene-edited CAR-T cell therapy targeting CD19 in development for the treatment of CD19+ malignancies, Gene editing approach: Disruption and insertion, Ownership: 100% owned by CRISPR Therapeutics, For more information on CTX110 please click here, Description: CTX120 is an allogeneic CRISPR/Cas9 gene-edited CAR-T cell therapy targeting BCMA in development for the treatment of multiple myeloma, For more information on CTX120 please click here, Description: CTX130 is an allogeneic CRISPR/Cas9 gene-edited CAR-T cell therapy targeting CD70 in development for the treatment of both solid tumors and hematologic malignancies, For more information on CTX130 please click here, Description: Allogeneic beta-cell replacement therapy derived from a CRISPR/Cas9 gene-edited immune-evasive stem cell line in development for the treatment of diabetes, Ownership: Co-development and co-commercialization with ViaCyte, Description: In vivo CRISPR/Cas9-based candidate in development for patients suffering from GSD Ia, a rare genetic disease caused by mutations in the G6PC gene encoding glucose-6-phosphatase. In addition to the venture funding, CRISPR Therapeutics has received funding from its corporate partners, Vertex Pharmaceuticals and Bayer AG, as well as institutional investors. CRISPR Therapeutics (NASDAQ:CRSP) may be one of the best biotechnology stocks to own in 2020. While the blood disorders area offers promise, the oncology (cancer treatment) pipeline has even greater potential to create dependable revenue streams. The technology’s ability to find and manipulate specific genes has also made it an everyday tool for exploring the biology of all living things and for diagnosing diseases. Going forward, we are interested in partnering with biopharma companies, academic centers, universities and other relevant organizations to access technologies and other capabilities. Copyright ©2020 Dow Jones & Company, Inc. All Rights Reserved. Careers at CRISPR, © 2020 CRISPR Therapeutics. Returns as of 10/08/2020. Gene editing has garnered the attention of investors and the pharma industry in the past decade, but what exactly is this innovative technique? 2 Best Gene-Editing Stocks to Buy in July, Copyright, Trademark and Patent Information. While CRISPR may have the lead in drug trials, the company is still relatively early in the development process and is nowhere near a product launch that could steer it toward regular recurring revenue. The stock is outpacing both the iShares Nasdaq Biotechnology ETF and S&P 500 by a wide margin, and looks positioned to charge higher over the long term. CRISPR Therapeutics has currently established significant collaborations with industry-leading Biopharma companies in Vertex Pharmaceuticals and Bayer AG. The Climb-111 trial demonstrated clinical proof of concept of CTX001 treatment on two patients with TDT with different genotypes. We've detected you are on Internet Explorer. According to CRISPR Therapeutics, CTX001 edits a patient's stem cells from within their bone marrow and instructs those cells to produce high levels of fetal hemoglobin (HbF) in their red blood cells. Emmanuelle Charpentier and Jennifer Doudna first proposed the idea of gene editing in 2012. Charpentier is at the Max Planck Institute in Berlin. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com. Returns as of 10/08/2020. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in CRISPR Therapeutics’ Annual Report on Form 10-K for the year ended December 31, 2019, as filed with the SEC on February 12, 2020, the prospectus supplement related to the public offering and other filings that CRISPR Therapeutics may make with the SEC in the future. https://www.barrons.com/articles/nobel-prize-for-gene-editing-innovators-boosts-crispr-therapeutics-and-other-stocks-51602079474. Meanwhile, Intellia's IND application was accepted by the Food and Drug Administration in March, and it will initiate its phase 1/2 trials this year. CRISPR Therapeutics and Vertex will jointly develop and commercialize CTX001 and equally share all research and development costs and profits worldwide. There are multiple types of gene editing, but the most promising approach is one that uses a CRISPR platform that allows scientists to alter an organism's DNA and potentially cure previously incurable diseases. Its share price is up over 37% year to date, while the share price for Editas has been flat. CRISPR's recent development successes in hematology treatment and CAR T-cell therapy for cancer offers tremendous upside and could catalyze the stock further with positive data near the second half of the year. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. CRISPR's management believes that its novel CAR T-cell therapy could offer a superior product over the current therapies that are limited in their ability to treat solid tumors and could offer a more effective therapy in the solid tumor cancer treatment space that's expected to be worth $425 billion by 2027. Editas Medicine Where Will Vertex Pharmaceuticals Be in 5 Years? On June 12, CRISPR Therapeutics and its partner Vertex Therapeutics reported positive news from phase 1/2 clinical trials of its lead compound, CTX001, for the treatment of two genetic diseases: Transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD).